Back to News
Market Impact: 0.15
Oncolytics Biotech Inc. Announces Translational Data for Pelareorep at SITC 2026 Annual Meeting
Source: Nasdaq
Healthcare & Biotech
Oncolytics Biotech announced new translational data from an ongoing Phase 1/2 Simon two-stage study of pelareorep in patients with second-line or later squamous cell anal cancer. The data were presented at the Society for Immunotherapy of Cancer 2026 Annual Meeting; the available article text does not provide findings or clinical outcomes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
ONCY0.45
More News
- How Abdul El-Sayed would build Medicare for All, from a wealth tax to a Fed-style governing board
- BillionToOne SVP John ten Bosch sells $320,723 in stock
- CVS Plans to Break Up $117 Billion Healthcare Conglomerate
- Sight Sciences earnings missed by $0.48, revenue topped estimates
- Novo raises full-year outlook as Wegovy sales impress
- Stifel raises Zimmer Biomet stock price target on strong quarter